

# 2021

## Corporate Responsibility Report



R.S., patient living with  
systemic mastocytosis

**CONTACTS**

**Jim Baker**  
Senior Vice President,  
Corporate Affairs

**Jenna Cohen**  
Senior Director, Investor Relations

ir@blueprintmedicines.com  
(617) 374-7580

**Blueprint Medicines Corporation**  
45 Sidney Street  
Cambridge, MA 02139  
USA

© 2022 Blueprint Medicines Corporation

**Table of Contents**

A message from our CEO ..... 1

Blueprint Medicines snapshot.....3

Patient access and community engagement .....6

Research and development.....10

Employees and culture.....14

Environmental sustainability .....20

Governance and integrity.....22

SASB data summary .....25



A Message  
from our CEO

**To our stakeholders:**

The reason Blueprint Medicines exists is to make a positive impact on the patients we serve, our employees, and the communities where we work and live. We are motivated every day by our shared mission – to change the outcomes and extend the lives of people who have received a diagnosis of cancer or a blood disorder.



Since we began operations just over a decade ago, Blueprint Medicines has become one of the world's leading independent precision therapy companies, with two approved medicines, a broad portfolio of therapeutic candidates, and a validated, highly productive research engine. More than 500 Blueprint Medicines employees in the U.S. and Europe are the lifeblood of our growing business, working with a profound sense of mission to drive our scientific innovation and deliver life-changing treatments to patients.

Today, as our company expands its reach to patients around the world, we are highlighting our ongoing commitment to good corporate citizenship with environmental, social, and governance (ESG) initiatives across the company aligned with our mission, core values, and culture. This corporate responsibility report – our first ever – is designed to share with our stakeholders a summary of this work, along with a range of sustainability metrics, for the 2021 calendar year.

Development of this report was coordinated by a cross-functional Corporate Responsibility Working Group, with oversight from our Executive Team and the Nominating and Corporate Governance Committee of our Board of Directors, and in it we highlight sustainability metrics aligned with the Sustainability Accounting Standards Board (SASB) standards for the Biotechnology and Pharmaceuticals Industry.

As I reflect on the progress we highlight within these pages, I am especially proud that:

- Today we are bringing our approved medicines AYVAKIT®/AYVAKYT® (avapritinib) and GAVRETO® (pralsetinib) to patients around the world and advancing a broad portfolio of investigational precision therapies with potential to dramatically expand our impact. Across the lifecycle of discovery, development, and commercialization, we are working closely with scientific and clinical experts, as well as patient communities, to innovate with the goal of improving outcomes.
- We are continuing to respond to the COVID-19 pandemic with thoughtfulness and urgency. In addition to giving our employees tools and resources to keep themselves and their families healthy, last year we implemented a hybrid model called BlueFlex to enable seamless integration of in-office and remote work environments and empower productivity and wellbeing. More broadly, we continue to implement creative solutions to help patients and physicians access our therapies and services while navigating the ongoing challenges

presented by COVID-19, from local lab testing and home delivery of study medication for clinical trial participants to technology solutions enabling remote compliant engagement with our commercial and medical teams.

- Earlier this year, we received the Top Workplaces USA award from Energage, which followed multiple additional awards we received in 2021 including recognition of our equity, diversity, and inclusion practices. These awards highlight the progress we have achieved in fostering a high-performance culture that celebrates collaboration, transparency, integrity, and diversity.
- We continue to make important impacts in our communities. In 2021, we worked with Alternatives for Community & Environment to raise awareness of environmental justice issues, Life Science Cares and American Chemical Society to recruit paid summer interns from groups underrepresented in the biopharmaceutical industry, and Holiday Hope Project to bring holiday gifts to children and families in need of support. In addition, our corporate match program continues to amplify the efforts of our employees to support non-profit organizations advancing social justice or providing humanitarian aid in our communities and around the world.

Importantly, we recognize that making good on our commitment to corporate responsibility is a journey that requires sustained effort. This report, which is intended to share our current activities more fully with our stakeholders, is an important but initial step forward. As we continue to make progress and advance our efforts, we look forward to receiving your feedback and insights, so that we can continue to realize our vision for making a positive impact on the world around us.

Warm regards,



**Kate Haviland**  
President and Chief Executive Officer  
Blueprint Medicines



## Snapshot

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders.

Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate our scientific innovation into a broad pipeline of important approved and investigational precision therapies aimed at addressing difficult-to-treat cancers and blood disorders.

In 2020, our first precision therapy, AYVAKIT, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFR D842V mutations. Subsequently, AYVAKIT was approved by the FDA in 2021 for the treatment of adults with advanced systemic mastocytosis (SM), including patients with aggressive SM, SM with associated hematologic neoplasm, and mast cell leukemia.

Also in 2020, GAVRETO was FDA approved for the treatment of adults with RET fusion-positive non-small cell lung cancer

(NSCLC), adults and pediatric patients with RET-mutant medullary thyroid cancer (MTC), and adults and pediatric patients with advanced RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory.

Today, we are delivering our approved medicines to patients in the United States, Europe, and in other geographies ourselves or through our partners. In addition, we are globally advancing multiple programs for SM, lung cancer, breast cancer, and other genomically defined cancers, and cancer immunotherapy.

Our Mission

We are working to make real the promise of precision therapy to improve and extend life for as many people with cancer and blood disorders as possible.

Our Core Values

We strive to uphold our Core Values every day, and we recognize, celebrate and recommit to these ideals together in many ways throughout the year – including through an annual Core Values Week celebration.



PATIENTS FIRST

We maintain intense focus on improving patients' lives



THOUGHTFULNESS

We explore creative approaches, daring to make well-thought-out decisions and owning the outcomes



URGENCY

We solve complex problems rapidly, with attention and care



TRUST

Through collaboration and cooperation, we build and maintain a cohesive team that has mutual respect of different viewpoints and talents



OPTIMISM

We pursue transformative therapies that we believe will make a difference



AWARDS AND RECOGNITION

2022 Top Workplaces USA  
Energage

2022 Top Workplaces USA  
Compensation & Benefits  
Energage

2022 Top Workplaces USA  
Purpose & Values  
Energage


2021 Top Workplaces USA  
Culture Excellence Award -  
DE&I Practices  
Energage

2021 Top Workplaces USA  
Culture Excellence Award –  
Top Managers  
Energage

2021 Top Workplaces USA  
Culture Excellence Award –  
Compensation  
Energage

Technology Fast 500™ 2021  
Recipient  
Awarded by Deloitte LLP

Outstanding Employer 2019  
Korn Ferry Engaged  
Performance Awards



<sup>1</sup>Includes two collaborations with Roche - one with Roche and Genentech, Inc. to develop and commercialize GAVRETO and another to discover, develop, and commercialize cancer immunotherapies.

<sup>2</sup>Data is reported as of April 4, 2022 to align with CEO and other leadership transitions effective as of that date.

<sup>3</sup>Excludes \$260 million in additional research and development expense related to the acquisition of Lengo Therapeutics, completed in late December 2021.





## Patient Access and Community Engagement

Patients are at the center of everything we do. At Blueprint Medicines, we believe we have the opportunity and responsibility to change what a diagnosis of cancer or blood disease will mean for patients, from something that is devastating and scary, to a diagnosis with treatment options that in sequence or in combination allow patients to maintain their health, their quality of life, and live longer.

### Patient Access

To achieve the impact we aim to make, we know that patients must be able to access our innovation. From the moment we demonstrated clinical proof-of-concept with our first precision therapy, we have considered patient access thoughtfully and with urgency. These efforts have included initiating global early access programs for our investigational therapies and designing a robust U.S. patient support program to assist patients access our commercially available medicines.

#### EARLY ACCESS PROGRAMS FOR INVESTIGATIONAL THERAPIES

We appreciate the urgency of patients and families facing a serious or immediately life-threatening disease when there are no standard treatment options available or treatment options have been exhausted, and we are committed to providing early access while maintaining our primary focus on moving investigational therapies through clinical trials and ultimately toward regulatory approvals.

Since we initiated our first early access program for avapritinib in 2018, we established and have adhered to criteria for considering requests for early access based on principles of transparency and equity. In addition, we have worked to make our therapies available to patients in need via access pathways around the world, including in countries where we do not have operations.

#### PATIENT SUPPORT PROGRAM FOR COMMERCIALLY AVAILABLE MEDICINES

To help patients residing in the U.S. access our commercially available medicines, we created YourBlueprint®, a comprehensive patient support program, tailored to the needs of patients and caregivers. YourBlueprint is designed to assist patients start and stay on therapy while minimizing out-of-pocket costs.

<sup>4</sup>In 2021, we transferred responsibility for all patient support services for GAVRETO® (pralsetinib) to our partner, Genentech, with whom we are co-commercializing GAVRETO in the U.S.

#### YOURBLUEPRINT PROGRAMS INCLUDE:

- **Co-pay assistance** for commercially-insured patients that can reduce costs to as little as \$0
- **Free drug for eligible patients** who have inadequate or no insurance coverage
- **Temporary treatment** to help address delays in insurance coverage
- **Dose exchange to offer no cost supply** to eligible patients in the event of a dose modification
- **Dedicated case manager** support navigating coverage and access issues as well as providing educational information

#### Access Highlights<sup>4</sup>

- **~4,700 patients worldwide** have received an approved or investigational Blueprint Medicines precision therapy from initiation of clinical development through the end of 2021
- **>500 patients worldwide** have received an investigational Blueprint Medicines precision therapy through a Blueprint Medicines early access program from program inception in 2018 through the end of 2021
- **Since the launch of AYVAKIT**, the majority of eligible U.S. patients have used the YourBlueprint co-pay support program, which lowers patient out of pocket costs to as little as \$0 per month
- **In 2021, ~30% of medication was provided** for free to U.S. AYVAKIT patients



David L., patient living with thyroid cancer, and family

#### PIONEERING THE SCIENCE OF TIME

Every day, we seek to transform science into more time for life. Time to be with families, time to be productive community members, time to feel the small moments of joy that shape our lives.





“

At Blueprint Medicines, we are committed to helping patients access our therapies, from removing financial barriers with our YourBlueprint® patient support program to addressing urgent medical needs with appropriate early access pathways.”

– Christy Rossi, Chief Operating Officer

## Community Engagement

A diagnosis of cancer or a rare blood disorder can be devastating and frightening, and patients and their families often face tremendous challenges throughout their disease journey, from obtaining a diagnosis, receiving optimal care, and learning to live with what is often a life-long condition. At Blueprint Medicines, we do more than deliver innovative treatments. We strive to be partners to the disease communities we serve in improving patient outcomes through innovative development, data generation, and education and support.

For example, we partnered closely with disease experts and The Mast Cell Disease Society to create a patient registry to collect data from patients that characterize the burden of SM and other mast cell disorders. More recently, we expanded this effort by working with the SM community to create the Touchstone initiative, which surveyed patients and healthcare providers in the U.S. to further improve understanding of SM and the burden of disease.

Data from these surveys, which were presented at the American Society of Hematology Annual Meeting in 2020 and recently submitted for peer-reviewed publication, show that SM symptoms have a profound impact on patients' lives. Compared to prior research on colorectal and lung cancer patients, participants reported worse physical functioning and mental health. In addition, more than half of patients reported reduced hours at work, and about one-third filed for medical disability due to their SM. Respondents cited the use of multiple over-the-counter and prescription medications, and frequent visits to physician specialists and the emergency department

to manage their SM. Altogether, these data highlighted the need for disease education, more rapid diagnosis, and better treatment to improve outcomes.

To address these needs, we are providing a range of tools and resources, including our ItsSMthing, TargetSM and UncoverKIT programs, to empower and inform patients and healthcare providers with information on the signs and symptoms of SM as well as diagnostic tools. Moreover, we have worked closely with commercial and academic laboratories in the U.S. to help them understand biomarker testing needs, and today, laboratories covering more than 80% of patients with SM provide highly sensitive, blood-based KIT D816V testing. In 2021, we also initiated a sponsored testing program with Labcorp to provide no-charge KIT D816V testing to eligible patients.

Beyond SM, we have also created programs and services to support additional patient populations. For example, we have created lung cancer clinical biomarker testing programs to address barriers to testing and help identify patients that may be eligible for enrollment in clinical studies of GAVRETO and, more recently, BLU-945 and BLU-701.

In addition, we recently initiated our Patient Council program, which involves standing advisory councils comprised of patients living with SM, lung, and thyroid cancer, respectively, to advise our cross-functional teams on program strategy, clinical trial design, and education and support initiatives. This structured insight sharing program is combined with frequent informal patient storytelling events, which enable our employees to hear directly from patients and caregivers living with the diseases we are seeking to address.



## A Case Study of Community Impact: Adopt-a-Family Program

We believe Blueprint Medicines can play an important role in improving the communities where we work and live, and we have sought to activate our company and employees as change agents through a variety of programs including:

- **Corporate match program** supporting employee donations to non-profit organizations advancing social justice and humanitarian aid
- **Company charitable contributions** to non-profit organizations focused on health and economic equity
- **Employee volunteer opportunities**, such as environmental clean-up and other community projects

One example of our community impact is our work with the Holiday Hope Project to create our Adopt-a-Family program, a celebrated annual company-wide activity focused on giving back to our community during the holiday season. Through this program, we reach local families and children in need with donated presents that are personally wrapped by our employees. In 2021, more than half of our employees came together to participate in our Adopt-a-Family program to help 43 families, including 193 individuals, with more than \$40,000 total donations.







## Research and Development

Precision therapy is a cornerstone of treatment for cancer and hematologic disease. However, early generation precision therapies are often limited by poor selectivity and off-target effects that limit dosing and therefore impact the durability of potential responses as well as open opportunities for the emergence of resistance.

Our founding scientists envisioned a new generation of precision therapies with enhanced selectivity to address these limitations. Highly selective compounds are able to achieve more potent target inhibition to enable rapid, deep, and durable responses. Selectivity is also important for limiting off-target effects, creating compounds that are well tolerated and able to combine with other agents to address and prevent tumor molecular evolution. To implement this vision, the first several years of our company’s existence were dedicated to building a scalable research platform to reproducibly and reliably discover potent and selective kinase inhibitors that address significant areas of medical need.

Eleven years after we began operations, Blueprint Medicines is one of the leading independent precision therapy companies in the world. We are the first company to achieve approval of

two homegrown medicines within 10 years, and our portfolio now includes 9 approved or investigational precision therapies, plus multiple undisclosed research programs, focused on core therapeutic areas in cancer and blood disease.

Today, we continue to invest in groundbreaking scientific research, building on our track record of research and development (R&D) success, to bring the promise of precision therapy to additional patient populations and their families. Recently, we began to expand our research platform to incorporate targeted protein degradation, a complementary therapeutic approach that leverages our annotated chemical library, new target discovery expertise and integrated development capabilities, with the goal of doubling our R&D productivity by 2025.

		<div><div></div> ongoing or completed</div> <div><div></div> planned</div>	Discovery	Early -Stage Development	Late-Stage Development	Regulatory Submission	Approved
Hematologic disorders	AYVAKIT® (avapritinib): KIT		Advanced SM <sup>1,2</sup>				U.S., Europe
			Non-advanced SM <sup>1</sup>				
	BLU-263: KIT		Non-advanced SM				
Genomically defined cancers	AYVAKIT® (avapritinib): PDGFRA		PDGFRA GIST <sup>1,3,4</sup>				U.S., Europe
	GAVRETO® (pralsetinib): RET		RET+ NSCLC <sup>1,3,5,6</sup>				U.S., Europe
			RET+ thyroid cancer <sup>1,3,5,7</sup>			MAA	U.S.
			Other RET+ solid tumors <sup>1,3,5</sup>				
	BLU-701: EGFR		EGFR+ NSCLC <sup>3,8</sup>				
	BLU-945: EGFR		EGFR+ NSCLC <sup>3,8</sup>				
	BLU-451: EGFR exon 20 insertions		EGFR+ NSCLC <sup>3</sup>				
Cancer immunotherapy	BLU-222: CDK2		CDK2-vulnerable cancers				
	BLU-852: MAP4K1		Advanced cancers <sup>9</sup>				
	Multiple undisclosed research programs						

<sup>1</sup>CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan.

<sup>2</sup>Approved in the U.S. for the treatment of adults with advanced SM, including aggressive SM, SM with an associated hematologic neoplasm and mast cell leukemia. Received marketing authorization in the European Union under the brand name AYVAKYT® for the treatment of adult patients with aggressive SM, SM with an associated hematological neoplasm or mast cell leukemia, after at least one systemic therapy.

<sup>3</sup>Unresectable or metastatic disease.

<sup>4</sup>Approved in the U.S. for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. Received conditional marketing authorization in the European Union under the brand name AYVAKYT® for the treatment of adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation.

<sup>5</sup>In collaboration with Roche. Blueprint Medicines and Roche have co-exclusive rights to develop and commercialize pralsetinib in the U.S., and Roche has exclusive rights to develop and commercialize pralsetinib outside the U.S., excluding the CStone territory.

<sup>6</sup>Received accelerated approval in the U.S. for the treatment of adults with metastatic RET fusion-positive NSCLC. Continued approval may be contingent on a confirmatory trial. Received conditional marketing authorization in Europe for the treatment of adults with advanced RET fusion-positive NSCLC not previously treated with a RET inhibitor.

<sup>7</sup>Received accelerated approval in the U.S. for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer. Continued approval may be contingent on confirmatory trials.

<sup>8</sup>Zai Lab has exclusive rights to develop and commercialize BLU-701 and BLU-945 in Mainland China, Hong Kong, Macau and Taiwan.

<sup>9</sup>In collaboration with Roche. Blueprint Medicines and Roche are conducting activities for up to two programs under the collaboration, including the program targeting MAP4K1. For one of the programs, Blueprint Medicines has U.S. commercial rights and Roche has ex-U.S. commercialization rights. For one of the programs, Roche has worldwide commercialization rights. GIST, gastrointestinal stromal tumors; MAA, marketing authorization application; NSCLC, non-small cell lung cancer; SM, systemic mastocytosis.

With a new era in precision medicine upon us and a growing new way of thinking about how cancer is treated based on tumor biomarkers rather than where the tumor is in the body or the type of tissue from which it developed, we also need to change the status quo in the identification and diagnosis of patients and in the development of their treatment plans. To this end, Blueprint Medicines has partnered widely across the healthcare ecosystem to bring our precision therapy innovation to patients around the world.

COLLABORATIONS AND LICENSES

Partnerships are an important part of our strategy to bring precision therapy innovation to patients with cancer and blood diseases around the world.

To globally advance our precision therapy programs, we are collaborating with:

- **Roche and Genentech**, a member of the Roche Group, to globally develop and commercialize GAVRETO for the treatment of RET-altered cancers
- **CStone Pharmaceuticals** to develop and commercialize avapritinib, fisogatinib and pralsetinib in Mainland China, Hong Kong, Macau and Taiwan
- **Zai Lab** to develop and commercialize BLU-945 and BLU-701 for the treatment of EGFR-mutant non-small cell lung cancer in Mainland China, Hong Kong, Macau and Taiwan

- **Roche** to discover, develop and commercialize small-molecule therapeutics targeting kinases believed to be important in cancer immunotherapy
- **Proteovant Therapeutics** to advance novel targeted protein degrader therapies
- **The University of Texas MD Anderson Cancer Center** to accelerate the development of BLU-222 for the treatment of CDK2 vulnerable cancers

In addition, we have a license agreement with:

- **Clementia Pharmaceuticals**, a subsidiary of Ipsen, for BLU-782, an investigational ALK2 inhibitor being developed for the treatment of fibrodysplasia ossificans progressiva

Research and Development Practices

We know that successful R&D requires collaboration and trust, especially with patients, families and healthcare providers who participate in clinical research, and we are dedicated to advancing patient safety, transparency, and equity in all our R&D efforts.

SAFETY OF CLINICAL TRIAL PARTICIPANTS

Across our clinical development programs, we follow all review and approval procedures required by applicable laws and regulations before initiating clinical research studies and throughout their conduct. All of our clinical trials are conducted by qualified Contract Research Organizations and overseen by qualified study managers in our clinical operations department who meet minimal prior experience requirements and are trained on our procedures through learning management systems. We protect patient safety

Diane L., patient living with lung cancer

PRECISION THAT MOVES

We help patients stay one step ahead with therapies that adapt to disease evolution. This includes solving for treatment resistance and intractable sites of progression, as well as pioneering innovative combinations to prolong benefit.



and well-being through appropriate informed consent, routine safety monitoring and reporting, and other procedures, including use of independent Data and Safety Monitoring Boards, consistent with established Good Clinical Practice guidelines and other country-specific standards.

PRODUCT QUALITY, SAFETY AND SUPPLY

We partner with leading industry organizations primarily in North America and Europe to develop and manufacture our therapies consistent with Good Manufacturing Practice regulations and guidelines. Our [Code of Business Conduct and Ethics](#) provides general guidelines for how we conduct business with the highest standards of ethics. While striving to work with Contract Development and Manufacturing Organizations that offer a broad range of technologies and capabilities, we maintain a robust program for supplier selection and qualification. This process enables us to select partners that align with our cultural values, promote diversity, equity, and inclusion, and hold themselves to the highest ethical, social, and environmental standards, in addition to having an impeccable compliance track record with relevant local and national authorities.

RESEARCH TRANSPARENCY

We recognize the importance of disclosing research, including clinical trial results, to ensure patients, healthcare providers, scientists, and other stakeholders are able to access information and data that can inform patient care and future research. We routinely share data from our preclinical and clinical studies with the scientific community through peer-reviewed publications in medical journals and presentations at conferences, as well as provide open access to key presentations and publications on [our website](#) for all stakeholders. In 2021, we submitted or published 121 presentations or publications, including seminal clinical trial

data publications in Nature Medicine, Lancet Oncology, and the Journal of Clinical Oncology. In addition, we register our clinical trials on ClinicalTrials.gov, EudraCT, and other relevant registry websites.

CLINICAL TRIAL TRAVEL SUPPORT PROGRAM

We know that clinical trials are often the last and only option for patients with advanced cancer for whom there are no standard therapies available and ensuring trial access is an important component of equitable care. To make our clinical trials accessible to patients regardless of their financial situation, we have put in place a clinical trial travel support program to remove barriers to participation. Through this program, we assist patients travel to clinical trial sites for study visits, with a caregiver such as a parent, spouse or partner, or other support person, by providing reimbursement of appropriate travel, accommodation, and meals.

DIVERSITY IN CLINICAL TRIALS

Enrolling patients with diverse backgrounds in clinical trials is critical to evaluating the potential of new medicines across populations with unique characteristics. As part of our efforts to increase diversity in our clinical trials, we provide translation of study materials, such as informed consent forms, and partner with patient advocacy groups to enable trial awareness and participation across diverse patient populations. To further expand our efforts to ensure all patients can benefit from our medical innovation, we recently assembled an internal working group of passionate R&D team members to strategize additional opportunities to increase diversity in trial design and execution, including through our partnerships with Contract Research Organizations and other stakeholders and optimization of trial procedures and communications.





## Employees and Culture

At Blueprint Medicines, we are committed to creating an environment where our employees feel a sense of belonging and are empowered to do their best work and thrive. We are intentional in how we build and nurture our culture to create transparency and foster trust. We believe that diversity, in all forms, is integral to our collective success, with the range of perspectives diversity brings forward enabling constructive debate and, ultimately, better outcomes to meet our goals.

Our core values are deeply ingrained principles that guide all our company actions and serve as our cultural cornerstones. Our employees are encouraged to live by these core values every day through our values-based rewards and recognition programs and held accountable through our feedback and performance review processes. Our employees are people first, so we provide them with comprehensive compensation, benefits, flexible work environment and schedules, and health and wellness offerings to help them be their best at work and at home. In addition, we create meaningful opportunities for professional development including a range of learning, mentorship, and skill builder programs.

### Our Culture Defined

Here at Blueprint Medicines, our culture is grounded in three core beliefs:

#### *We're better together.*

Connection and collaboration across disciplines is critical to accomplish our mission. We create space for diverse perspectives and backgrounds which makes us stronger because we are more creative and ultimately successful when multiple voices are part of the conversation.

#### *We live courage and integrity.*

We do hard things, and we don't turn away from a challenge when it's an opportunity. We take calculated risks, push boundaries and defy obstacles. This is part of our DNA: to be lifelong learners. We do the right thing and set the bar high. We own our decisions and admit our mistakes.

#### *We are human.*

In order to remain focused on what matters most – extending and improving the lives of patients – we believe in showing up as we are while embracing our imperfections. We empower ourselves to take calculated risks, make critical decisions quickly, and pave our own path. We prioritize health and well-being because we can't go the distance unless we take care of ourselves and each other.



“

Our ED&I strategy leads with equity because we know that even in organizations that are diverse and inclusive, individuals who come from different backgrounds can still run into policies, practices, and assumptions that prevent them from being fully engaged and feeling a sense of belonging. By elevating equity, we aim to support all our employees in reaching their full potential.”

– Debbie Bumpus, Chief People Officer



### DIVERSITY SPARKS INNOVATION

Our diverse team is passionate about science and thrives on working together to achieve the impossible. We use every opportunity to think differently, make bold decisions and pioneer novel solutions.



Talent Recruitment

Creating a workforce of best-in-class scientists, clinicians, business and technical experts, managers and executive leaders requires a foundation of people who are thoughtful and driven and hold technical expertise. In order to build a strong recruitment and development program, we have established a number of opportunities to attract top-tier talent at all levels of the organization including internships, fellowships, and post-doctoral programs. In addition, we created a business operations fellowship program for high-potential early career business professionals, as well as participate in external talent development initiatives such as MassBioEd's Apprenticeship Program.

Employee Experience

At Blueprint Medicines, we have designed a rich, flexible employee experience that is responsive to continuous feedback and insights and enabled by a culture of learning and development.

ENGAGEMENT

We routinely seek out and action employee feedback and insights to optimize the employee experience, including through our annual Engagement and Enablement Survey. In 2021, 93% of our global workforce completed the survey, revealing:

96%

are proud to work at Blueprint Medicines

90%

are excited to be a part of our future

95%

know how their role contributes to our goals

91%

believe the company's commitment to equity, diversity and inclusion is genuine

98%

feel they have a good understanding of our core values

RETENTION AND DEVELOPMENT

We take a thoughtful approach to retaining talent with a focus on fostering alignment on mission, values, and culture, enabling rich experiences and opportunities for growth, supporting work environment and schedule flexibility, and celebrating employees with a robust rewards and recognition program. As a result, we have achieved a voluntary turnover rate below the industry average throughout our history as a company, including in 2021.

We are lifetime learners which propels a culture of learning and enables an accelerated pace to our workforce development. We foster this through broad roles with an expansive responsibility set, experiential leadership development, as well as skill and competency building programs.

Examples of these programs include:

- **Blue University and e-learning training center** provide training and learning resources
- **Our mentorship program** pairs employees across level and function to foster technical and leadership skill building as well as connection
- **BOLD Leadership program** teaches leadership skills to high-potential mid-level managers.
- **Senior Leadership Circle**, a community of senior-level managers, creates opportunity for functional leaders to engage with executives on enterprise strategy
- **Quarterly reflection exercises** which include goal check-up, priority re-alignment, and giving and sharing feedback with colleagues

BENEFITS

Our Total Rewards program prioritizes choice, flexibility and inclusion, enabling employees to access benefits that work well for themselves and their families. These benefits include:

- Competitive short-term and long-term incentive compensation and employee stock purchase plan
- Comprehensive medical, dental and vision plans and a retirement savings program with company match
- 12-week family leave at 100% pay for qualifying reasons including parental leave or to care for an immediate family member with a serious health condition
- Career, lifestyle and productivity coaching
- Two 1-week well-being shutdowns (summer and winter)
- Perks such as GrubHub stipends, commuter benefits and premium access to Headspace and Modern Health

Equity, Diversity, and Inclusion

At Blueprint Medicines, we know that diverse perspectives make us stronger and help us achieve better outcomes for the patients we serve. We believe if we can help our people show up as their authentic selves every day, they will have an improved sense of overall well-being making them more engaged and productive, thereby driving our company performance.

Our comprehensive equity, diversity, and inclusion (ED&I) strategy aims to cultivate a culture of ED&I at Blueprint Medicines and within the communities we live and work. We do this by actively recruiting diverse talent at all levels of the company, creating an environment that enables employees from underrepresented groups to thrive, and engaging externally to impact communities.

This focus on ED&I has been prioritized and embedded into our culture by our leadership since our founding. More recently, we expanded our approach with the creation of an ED&I Committee in 2020, which today involves a significant proportion of our global workforce, including members of our Executive Team, reflecting the deep commitment of our employees and management. This group serves to ideate and action ED&I initiatives across the company, including culture, workforce, and external activities, as well as advise executive and functional leadership. We were honored to be recognized for our ED&I work with a 2021 Top Workplaces Culture Excellence Award for Diversity, Equity and Inclusion practices.

ED&I PROGRAMS AND ACTIVITIES

Representative ED&I programs and activities in 2021 included:

- Development of corporate, functional, and manager level goals related to ED&I, including areas of focus centered on awareness, education, and training and talent recruitment
- Unconscious bias training incorporated into our core curriculum for all employees
- Quarterly ED&I Circle employee discussion forums enabling safe, supportive space for reflection and dialogue on important social topics and issues
- Incorporation of Textio artificial intelligence to address biases in job description language
- Internship program partnered with Life Science Cares and American Chemical Society achieved approximately 75% participation from underrepresented groups
- Company match program that continues to match employee charitable cash donations and volunteer hours to organizations advancing social justice
- Community sponsorships to non-profit organizations promoting ED&I, such as Women of Color in Pharma, OutBio, and Life Science Cares





# Global Company Snapshot

## Blueprint Medicines Employees

515

Total employees

478

U.S. employees

## Global Gender Diversity (%)

56%

Female

44%

Male

## Racial Diversity of U.S. Workforce (%)

0%

American Indian or Alaska Native or Pacific Islander

21%

Asian

5%

Black or African American

4%

Hispanic or Latino

1%

Two or more races

62%

White

## Executive Team

12

Members

6

Female members

4

Members from underrepresented populations

## Board of Directors

10

Members

3

Female members

1

Member from underrepresented populations

Data is reported as of April 4, 2022 to align with CEO and other leadership transitions effective as of that date. Underrepresented populations defined as those who self-reported as Black or African American, Hispanic or Latino, American Indian, Alaska Native or Pacific Islander, LGBTQ+, or who identified as two or more races.



## Health and Safety

We are committed to protecting the health, wellbeing, and safety of our employees, and we have robust systems in place aligned with federal, state, and local regulations and managed by our facilities team under the oversight of our Chief Financial Officer.

All employees receive new hire safety training which includes general safety, fire safety, emergency evacuation procedures, exposures and medical emergencies, and other topics consistent with regulation and standard practice. In addition, employees working in our laboratories receive additional annual trainings on potential emergency situations and procedures, including chemical spills and exposures.

We conduct yearly audits of our office space and laboratories to ensure proper emergency planning and equipment, proper hazardous and biological waste handling, fire safety, and other areas. The company maintains an emergency action plan, updated and reviewed yearly by a designated Emergency Coordinator. This emergency action plan includes information on emergency evacuation, medical, chemical, and biohazard emergencies, natural disasters, and other events.

## RESPONDING TO THE COVID-19 PANDEMIC

We believe deeply in our responsibility to prioritize and safeguard public health. As we have navigated the COVID-19 pandemic, our response has been led with urgency, thoughtfulness, and a people-first approach to help our employees thrive and continue doing what they do best: deliver transformative therapies to patients in need.

To support our employees, our response has included:

- **Rapid implementation of safety practices**, including COVID testing, masking, contact tracing, and social distancing, consistent with or exceeding national and local public health guidance
- **Free COVID testing** for employees
- **Activation of a new hybrid work model** enabling employees to choose a mix of remote and in-office working environments, supported by dynamic upgrades to our office workspace and IT collaboration tools to enable seamless productivity, connection, and collaboration
- **Launch of free, full-access membership** to Modern Health and Headspace to support employees and their dependents in prioritizing mental health and general wellbeing

In addition, to support our broader community, our response has included:

- **Implementation of practices and procedures** across our business to ensure continued patient access to our commercially available and investigational therapies. For example, we have worked with clinical trial sites to ease burden on patients through use of local laboratories for testing, home delivery of study medication, and remote data and records monitoring
- **Donations of personal protective equipment** to front-line workers
- **Charitable donations** to patient advocacy groups to support them in the earlier stages of the pandemic

The onset of the pandemic impacted our lives and brought forward an opportunity for all in a changed world. Here at Blueprint Medicines, our commitment to our mission has never been more important and we have embraced these learnings to propel us forward.

## Environmental Sustainability

Blueprint Medicines is devoted to improving the health of patients through innovative science, and we believe part of this commitment includes a responsibility to care for our environment. As a global company, we are committed to limiting our impact on the environment and working with stakeholders to improve awareness and action on sustainability initiatives.

Established in 2018, our Green Team coordinates internal initiatives and education to raise awareness and provide resources on environmental issues. Through this team, we have championed waste reduction programs, commuter benefits, and sponsored educational events for our employees to help understand how environmental justice initiatives benefit our community.

In addition, we are working to expand our sustainability efforts as our company continues to grow, including efforts to collect data across multiple areas to monitor our impact over time.

### Energy, Waste, and Water

We are committed to operating our business in a sustainable manner and limiting our environmental impact, and we have initiated a number of programs to advance these interests.

#### COMMUTER BENEFITS AND TELECOMMUTING

We provide commuter and telecommuting benefits to our employees, including bike-to-work, public transportation subsidies, and electric vehicle charging stations, with the goal of reducing emissions associated with commuting. This includes the build-out of a bike storage and maintenance room in our Cambridge headquarters. In addition, during the COVID-19 pandemic, we implemented a permanent flexible work model enabling telecommuting supported by the introduction of collaboration technologies.

#### ENERGY EFFICIENT SYSTEMS

To limit our energy use, we have installed high-efficiency LED lighting, with automatic shut-off timers and motion sensors throughout our Cambridge headquarters. In addition, we have put in place systems, such as proximity sensors to improve HVAC system efficiency, to effectively manage energy utilization in our laboratories.

#### COMPOSTING PROGRAM

Beginning in 2019, we initiated a composting program in our Cambridge headquarters. In the first year of the program, we diverted approximately 20,000 pounds of compostable material to create approximately 10,000 pounds of finished compost. This program was suspended in 2020 due to the COVID-19 pandemic and reinstated in mid-2021. As part of this initiative,

we began to use compostable materials, including utensils, cups, and plates, in our cafeteria.

#### PAPER MANAGEMENT EFFORTS

We have implemented initiatives to manage paper waste, including paper recycling collection throughout our Cambridge headquarters, electronic contract management and signature collection, and promotion of eco-friendly printing such as default 2-sided print settings for office printers.

#### WATER USAGE AND WASTEWATER MANAGEMENT

We use a reverse osmosis water filtration system to provide purified water to our Cambridge headquarters, with reject water diverted for use in non-potable water applications prior to sewer discharge. In addition, we pre-treat laboratory wastewater daily before it is discharged, and our scientists receive new hire and annual trainings including wastewater management procedures.

#### HAZARDOUS WASTE REDUCTION AND LABORATORY MANAGEMENT

Our hazardous waste program ensures that we comply with all relevant local, state and federal regulations for proper signage, storage, labeling, transporting and disposal of waste, and routine internal inspections are conducted to ensure compliance. In addition, we recently implemented a recycling program for laboratory materials, such as pipette tip boxes, wafers, lids, media bottles, and conical tub racks.

#### EMPLOYEE EDUCATION INITIATIVES

Our Green Team frequently sponsors educational activities to raise employee awareness of sustainability topics, including an annual Earth Day celebration, employee challenge activities focused on waste reduction, and a bike clinic.

In 2021, our Green Team and ED&I Committee co-led a special educational seminar on environmental justice with community leaders from Alternatives for Community and Education (ACE) to raise awareness of the intersection of racism, economic inequality, and environmental issues. This event took our employees on a virtual Toxic Tour of the Boston community, highlighting neighborhoods adversely impacted by environmental hazards as well as the actions ACE and other organizations took to address these issues.



## Governance and Ethics

Under the leadership of our Board of Directors and Executive Team, we are committed to good governance as an essential business practice and component of our corporate responsibility efforts. We adhere to high ethical, compliance, and legal standards in everything we do.

### Corporate Governance

Our Board of Directors believes that good corporate governance is important to ensure that our company is managed for the long-term benefit of stockholders and has adopted a [Code of Business Conduct and Ethics](#) that applies to our directors, officers, and employees, as well as [Corporate Governance Guidelines](#) to assist in the exercise of the Board's duties and responsibilities. Our Board members each bring distinct scientific, clinical, and business backgrounds to their roles, which provide diverse experiences and perspectives to their oversight of the company. Led by Executive Chair Jeff Albers and Lead Independent Director Lynn Seeley, our Board includes four key committees:

- Audit Committee ([see charter](#))
- Compensation Committee ([see charter](#))
- Nominating and Corporate Governance Committee ([see charter](#))
- Research and Development Committee ([see charter](#))

In late 2021, the Nominating and Corporate Governance Committee expanded its oversight to include corporate responsibility and ESG-related matters. This followed the creation of a Corporate Responsibility Working Group in 2021, which is comprised of functional leaders from across the company including clinical development, market access, human resources, legal, compliance, finance, information technology, facilities, technical operations, and corporate affairs. The Working Group compiles and reviews reporting and key performance indicators across multiple domains and advises on corporate responsibility initiatives.

### Ethics and Integrity

Integrity is fundamental to everything we do at Blueprint Medicines. We have established a [Comprehensive Compliance Program](#) to set the standards for how we conduct business

with integrity, and to communicate to all Blueprint personnel, agents and contractors acting on Blueprint Medicines' behalf our expectations to operate in accordance with ethical business practices and our core values.

Our program is based on the seven elements of an effective compliance program as outlined in the Compliance Program Guidance for Pharmaceutical Manufacturers issued in 2003 by the Office of the Inspector General of the Department of Health and Human Services. Blueprint Medicines has adopted the Pharmaceutical Research and Manufacturers of America Code and has implemented policies and procedures that are consistent with its requirements. We audit our program periodically to meet evolving compliance needs as well as additional laws and guidance.

Blueprint Medicines has a Chief Compliance Officer who has overall responsibility for the Compliance Program with direct access to our Chief Executive Officer and provides annual reports to the Board of Directors concerning our program. We have also appointed a global Compliance Committee, consisting of senior cross-functional leadership from compliance, legal, medical, finance, commercial, international, and patient advocacy, which provides management oversight of our program.

We have a [Code of Business Conduct and Ethics](#) that guides us in making ethical and legal decisions when conducting Blueprint Medicines business and performing day-to-day duties. The Code has been made available to all employees via our internal website and new hires receive a copy of the Code and must attest that they have reviewed it. In addition, we provide training to employees in Europe that integrates elements of the European Federation of Pharmaceutical Industries and Associations Code to address region-specific considerations.

“

Integrity is fundamental to how we work with each other and how we interact with our external stakeholders and the communities in which we work.”

– Tracey McCain, Executive Vice President, Chief Legal and Compliance Officer





Blueprint Medicines only promotes products for uses that have been approved by appropriate regulatory authorities, and all promotional materials must meet the requirements of applicable local laws, regulations, and industry codes. In addition, we have clear standards for responding to unsolicited requests for information about our unapproved products or unapproved uses of our approved products. Internal compliance policies on promotional interactions and non-promotional medical interactions are part of our core employee training. In addition, we launched a U.S. Field Manual in 2021 to provide a comprehensive guidance resource on compliance policies to support our U.S. field personnel.

Education and training are essential to effectively communicate our standards and expectations. All U.S. and ex-U.S. employees including part-time and certain contractors are trained on compliance policies and guidelines that are applicable to their job functions. In addition, we held our first annual Integrity Day in 2021 to further foster a culture where every employee is accountable to act with courage, feels empowered to use their voice to speak up, and does the right thing.

Data Privacy

We recognize the importance of protecting the privacy of personal information and other confidential information. Our employees are dedicated and proficient, acting as data stewards across various areas, expertise, and professions,

to protect the personal data of patients, caregivers, and the healthcare professionals who support them. Employees are required to participate in annual data privacy training, and we follow a defined data security protocol focusing on handling data safely and transparently in agreement with international laws and regulations governing data protection and privacy.

Blueprint Medicines concentrates on securing, testing, and optimizing our technology ecosystem, ensuring the integrity of our data and the data of patients. We proactively initiate monthly cybersecurity assessments, periodic phishing awareness campaigns, and annual information security training in addition to monitoring threats in real-time using various modern technologies. In 2020, we pivoted from a heavily onsite work model to a flexible remote work culture by swiftly implementing technology capabilities and modifying our application and hardware lifecycles to secure and support this rapid change.

The Audit Committee of our Board of Directors receives updates regarding matters of information technology security and relevant data matters. The Data Privacy Taskforce, which is comprised of a cross-functional team led by the legal department, oversees data processing activities and adherence to global privacy regulations. We have established a privacy incident investigation and management process for responding to potential data breach incidents. In addition, we have established a [Privacy Policy](#) which is publicly available on our website.

SASB Data Summary

Blueprint Medicines has adopted accounting standards for the biotechnology and pharmaceuticals industry from the Sustainability Accounting Standards Board (SASB) to help develop and prioritize areas for inclusion in our Corporate Responsibility Report. Following is a table of relevant SASB accounting metrics.

SASB Code	Accounting Metric	2021 Disclosure
SAFETY OF CLINICAL TRIAL PARTICIPANTS		
HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	Refer to Corporate Responsibility Report, <a href="#">R&amp;D Section</a> .
HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	No trials were inspected that resulted in classification of VAI/OAI.
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	No material losses resulting from legal proceedings.
ACCESS TO MEDICINES		
HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	Refer to Corporate Responsibility Report, <a href="#">Patient Access and Community Engagement Section</a> .
HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	We do not have any products that qualify for the WHO List of Prequalified Medicinal Products.
AFFORDABILITY AND PRICING		
HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	We believe the price of our medicines reflects their profound benefits in rare, genomically defined patient populations for which they are developed to treat.
HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	We're committed to enabling patient access, and we've designed a robust patient support program in the U.S. to help patients start and stay on therapy while minimizing out-of-pocket costs. In addition, we're committed to reinvesting product revenues into research to bring even more treatment advances to patients with cancer and blood diseases.  We periodically consider price increases consistent with inflation and our goal to sustain our R&D efforts. In 2021, we enacted a 4.9% price increase in the U.S. for AYVAKIT. There was no change in the price of GAVRETO.



SASB Code	Accounting Metric	2021 Disclosure
<b>DRUG SAFETY</b>		
<b>HC-BP-250a.1</b>	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	No Blueprint Medicines products are currently listed in the MedWatch Safety Alerts database. The FDA MedWatch Safety Alerts for Human Medical Products database can be publicly accessed <a href="#">here</a> .
<b>HC-BP-250a.2</b>	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	This information for our products can be found in the FDA's Adverse Event Reporting System <a href="#">here</a> .
<b>HC-BP-250a.3</b>	Number of recalls issued, total units recalled	There were no recalls issued.
<b>HC-BP-250a.5</b>	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	We have not had any GMP violations or enforcement actions.
<b>COUNTERFEIT DRUGS</b>		
<b>HC-BP-260a.1</b>	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	We have implemented fully compliant serialization practices into our supply chain for commercial products such that every unit has a unique identifier, enabling the relevant parts of product supply chain to be halted if a transaction takes place involving a falsified product.
<b>HC-BP-260a.2</b>	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	We have internal processes in place to ensure risks associated with unsafe products are managed. As of December 31, 2021, no alerts have been received.
<b>HC-BP-260a.3</b>	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	None.
<b>ETHICAL MARKETING</b>		
<b>HC-BP-270a.1</b>	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	No material losses resulting from legal proceedings.
<b>HC-BP-270a.2</b>	Description of code of ethics governing promotion of off-label use of products	Refer to Corporate Responsibility Report, <a href="#">Governance and Ethics section</a> .
<b>EMPLOYEE RECRUITMENT, DEVELOPMENT, AND RETENTION</b>		
<b>HC-BP-330a.1</b>	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	Refer to Corporate Responsibility Report, <a href="#">Employees and Culture section</a> .
<b>HC-BP-330a.2</b>	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	Refer to Corporate Responsibility Report, <a href="#">Employees and Culture section</a> .

SASB Code	Accounting Metric	2021 Disclosure
<b>BUSINESS ETHICS</b>		
<b>HC-BP-510a.1</b>	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	No material losses resulting from legal proceedings.
<b>HC-BP-510a.2</b>	Description of code of ethics governing interactions with health care professionals	Refer to Corporate Responsibility Report, <a href="#">Governance and Ethics section</a> .
<b>ACTIVITY METRICS</b>		
<b>HC-BP-000.A</b>	Number of patients treated	Approximately 4,700 total patients treated with a commercially available or investigational therapy from initiation of clinical development through the end of 2021.
<b>HC-BP-000.B</b>	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	Our portfolio includes 9 precision therapies. This includes 2 approved medicines, which are also being evaluated for additional indications, as well as 6 investigational therapies in Phase 1-3 clinical development for initial indications and 1 in preclinical development. <sup>5</sup>

<sup>5</sup>Includes BLU-782, which is out-licensed to Ipsen.

Forward-Looking Statements

This Corporate Responsibility Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans and expectations for Blueprint Medicines’ current or future approved drugs and drug candidates; the potential benefits of any of Blueprint Medicines’ current or future approved drugs or drug candidates in treating patients; and Blueprint Medicines’ strategy, goals and anticipated milestones, business plans and focus. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this report are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this report, including, without limitation, risks and uncertainties related to the impact of the COVID-19 pandemic to Blueprint Medicines’ business, operations, strategy, goals and anticipated milestones, including Blueprint Medicines’ ongoing and planned research and discovery activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Blueprint Medicines’ ability and plans in continuing to establish and expand a commercial infrastructure, and successfully launching, marketing and selling current or future approved products; Blueprint Medicines’ ability to successfully expand the approved indications for AYVAKIT/AYVAKYT and GAVRETO or obtain marketing approval for AYVAKIT/AYVAKYT in additional geographies in the future; the delay of any current or planned clinical trials or the development of Blueprint Medicines’ current or future drug candidates; Blueprint Medicines’ advancement of multiple early-stage efforts; Blueprint Medicines’ ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the preclinical and clinical results for Blueprint Medicines’ drug candidates, which may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines’ ability to obtain, maintain and enforce patent and other intellectual property protection for AYVAKIT/AYVAKYT, GAVRETO or any drug candidates it is developing; Blueprint Medicines’ ability to develop and commercialize companion diagnostic tests for AYVAKIT/AYVAKYT, GAVRETO or any of its current and future drug candidates; Blueprint Medicines’ ability to successfully expand its operations, research platform and portfolio of therapeutic candidates, and the timing and costs thereof; Blueprint Medicines’ ability to realize the anticipated benefits of its executive leadership transition plan; and the success of Blueprint Medicines’ current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Blueprint Medicines’ filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines’ most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this report represent Blueprint Medicines’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

Blueprint Medicines, AYVAKIT, AYVAKYT, GAVRETO, YourBlueprint and associated logos are trademarks of Blueprint Medicines Corporation.

NOT FOR PROMOTIONAL USE







**Blueprint Medicines Global Headquarters**

45 Sidney Street  
Cambridge, MA 02139  
USA

**Blueprint Medicines (Switzerland) GmbH**

Baarerstrasse 8  
6300 Zug  
Switzerland

[blueprintmedicines.com](http://blueprintmedicines.com)

NASDAQ: BPMC

